Stephen Hoge Sells 160,009 Shares of Moderna (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 160,009 shares of Moderna stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares in the company, valued at $71,180,734.68. The trade was a 9.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Moderna Stock Up 0.7%

Shares of NASDAQ:MRNA opened at $51.71 on Friday. The company has a 50 day moving average price of $40.67 and a two-hundred day moving average price of $31.12. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. The company has a market capitalization of $20.42 billion, a PE ratio of -7.11 and a beta of 1.32. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $55.20.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.79) by $0.68. The company had revenue of $678.00 million during the quarter, compared to analyst estimates of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The firm’s revenue was down 33.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.91) EPS. Analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently modified their holdings of MRNA. Rothschild Investment LLC increased its position in shares of Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after acquiring an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in Moderna in the second quarter valued at approximately $26,000. MUFG Securities EMEA plc acquired a new position in shares of Moderna during the 2nd quarter worth approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Moderna during the 4th quarter worth approximately $31,000. Finally, Cromwell Holdings LLC boosted its holdings in shares of Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after buying an additional 341 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent analyst reports. Citigroup reiterated a “neutral” rating on shares of Moderna in a report on Monday, February 16th. Bank of America dropped their target price on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. The Goldman Sachs Group upped their price target on shares of Moderna from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Tuesday, February 17th. Piper Sandler increased their price objective on shares of Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Evercore set a $35.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. Two research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of “Reduce” and a consensus price target of $31.87.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.